The nationally and internationally recognized research team of the OSUCCC – James Green Lab comprises world-renowned scientists who are working to gain a better understanding of how the T-cell leukemia virus type 1 (HTLV-1) progresses into leukemia. The goal? To develop potential novel therapeutics to treat this virus.
A recent Green Lab discovery revealed the importance of a viral gene (called Hbz) in the maintenance and proliferation of HTLV-1 infected cells. Hbz is the only viral gene consistently expressed in HTLV-1 associated adult T-cell leukemia/lymphoma, and the gene, along with the cellular pathways it impacts, are important targets for the treatment and prevention of HTLV-1-associated diseases.
Additional Accomplishments
The Green Lab has the distinction of having the longest running National Institutes of Health/National Cancer Institute Program Project Grant at The Ohio State University. They received the competitive P01 grant renewal that will run through 2025 for the project entitled, “Retrovirus Models of Cancer.”
This renewal award totals $9.1 million and is funded by the National Cancer Institute. The ultimate goal of this integrated multidisciplinary and multi-institutional program project grant is to utilize an HTLV-1 T-cell immortalization model to gain understanding of the microenvironmental, cellular and viral factors that lead to the progression to leukemia.
Recent publications include:
View a full list of publications
For more information on the team, collaborations, opportunities and lab-specific inquiries, please contact green.466@osu.edu or visit https://vet.osu.edu/PatrickGreen.